Progenics Pharmaceuticals, Inc.

Clinical trials sponsored by Progenics Pharmaceuticals, Inc., explained in plain language.

Now part of Lantheus Holdings, Inc. LNTH NASDAQ

Biopharmaceutical company developing oncology therapies.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1

Radioactive therapy shows promise for tough prostate cancer

Disease control Completed

This phase 2 trial tested whether adding a radioactive drug (I-131-1095) to standard enzalutamide therapy helps men with a specific type of advanced prostate cancer that had worsened on another treatment. The study enrolled 120 men with PSMA-positive metastatic castration-resista…

Phase 2 • Sponsor: Progenics Pharmaceuticals, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:54 UTC

Progenics Pharmaceuticals, Inc.

Radioactive therapy shows promise for tough prostate cancer